| scholarly article | Q13442814 |
| editorial | Q871232 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1016783050 |
| P356 | DOI | 10.1038/TP.2012.28 |
| P932 | PMC publication ID | 3337069 |
| P698 | PubMed publication ID | 22832907 |
| P5875 | ResearchGate publication ID | 230568742 |
| P50 | author | Michael Valenzuela | Q37782209 |
| P2093 | author name string | H Brodaty | |
| K Ritchie | |||
| M Esler | |||
| P2860 | cites work | Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. | Q52171111 |
| Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? | Q52974532 | ||
| Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. | Q53211318 | ||
| Expression and distribution of beta amyloid precursor protein and beta amyloid peptide in reactive astrocytes after transient middle cerebral artery occlusion. | Q53243101 | ||
| Mixed dementia--the most common cause of dementia. | Q53356039 | ||
| Cerebral ischemia and Alzheimer's disease: the expression of amyloid-beta and apolipoprotein E in human hippocampus. | Q53390971 | ||
| Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. | Q54132112 | ||
| Apolipoprotein E Alleles and Risk of Coronary Disease | Q57740650 | ||
| Computed tomographic patterns of proven embolic brain infarctions | Q69414422 | ||
| 15-year longitudinal study of blood pressure and dementia | Q71021081 | ||
| Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators | Q71235684 | ||
| Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils | Q71736000 | ||
| Untreated hypertension among Australian adults: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab) | Q73717812 | ||
| Staging of Alzheimer-related cortical destruction | Q74108694 | ||
| White matter lesions and hippocampal atrophy in Alzheimer's disease | Q75338301 | ||
| When will dementia become a curable disease and Alzheimer's a forgotten word? | Q84214742 | ||
| Forecasting the global burden of Alzheimer’s disease | Q22252403 | ||
| Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia | Q24246379 | ||
| Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory | Q24645499 | ||
| Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease | Q24675823 | ||
| Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease | Q28216782 | ||
| Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum | Q28262806 | ||
| Hypertension in adults across the age spectrum: current outcomes and control in the community | Q28263835 | ||
| Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial | Q28286628 | ||
| Alpha 1-antichymotrypsin | Q28297469 | ||
| Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies | Q28306571 | ||
| Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group | Q28328155 | ||
| Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study | Q28366850 | ||
| Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment | Q29547294 | ||
| Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. | Q31586339 | ||
| Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial | Q31834521 | ||
| The neuropathology of probable Alzheimer disease and mild cognitive impairment | Q33616561 | ||
| Differentiation of vascular dementia from AD on neuropsychological tests | Q33733780 | ||
| Hypertension is a potential risk factor for vascular dementia: systematic review | Q33873945 | ||
| Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia | Q33888793 | ||
| Contribution of vascular pathology to the clinical expression of dementia | Q33926682 | ||
| Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). | Q33935314 | ||
| Aggregation of vascular risk factors and risk of incident Alzheimer disease | Q33989502 | ||
| The Significance of Cerebral White Matter Abnormalities 100 Years After Binswanger’s Report | Q34299420 | ||
| Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers | Q34396204 | ||
| Small artery remodeling in hypertension. | Q34492807 | ||
| Hypertension and cerebrovascular diseases: a specific role of vascular protection for the prevention of dementia. | Q34506208 | ||
| Mixed dementia: emerging concepts and therapeutic implications | Q34553430 | ||
| Neuropathology of white matter lesions in vascular cognitive impairment | Q34568772 | ||
| Treatment of hypertension in patients 80 years of age or older | Q34766135 | ||
| Hypertension and cognitive function: Pathophysiologic effects of hypertension on the brain | Q35118333 | ||
| Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression | Q35214758 | ||
| Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies | Q35595432 | ||
| Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study | Q35621059 | ||
| The age-dependent relation of blood pressure to cognitive function and dementia | Q36201875 | ||
| Risk of dementia in diabetes mellitus: a systematic review | Q36345254 | ||
| Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults | Q36598021 | ||
| The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis | Q36807001 | ||
| Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease | Q36934762 | ||
| Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. | Q37095385 | ||
| Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons | Q37196206 | ||
| Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension | Q37239502 | ||
| Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. | Q37299819 | ||
| Variations in the transcriptome of Alzheimer's disease reveal molecular networks involved in cardiovascular diseases | Q37384944 | ||
| Neuroprotective effects of blockers for T-type calcium channels. | Q37415013 | ||
| Contribution of hypoxia to Alzheimer's disease: is HIF-1alpha a mediator of neurodegeneration? | Q37599399 | ||
| Spontaneously hypertensive rat neuroanatomy: applications to pharmacological research | Q37809017 | ||
| Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. | Q37846798 | ||
| Risk factors and preventive interventions for Alzheimer disease: state of the science | Q37873674 | ||
| Is low-renin hypertension a stage in the development of essential hypertension or a diagnostic entity? | Q39318677 | ||
| Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study | Q39982469 | ||
| Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. | Q40038717 | ||
| Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study | Q40297061 | ||
| Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study | Q40350995 | ||
| beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity | Q41089179 | ||
| Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer's disease. | Q42069122 | ||
| Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia | Q42168781 | ||
| Brain infarction and the clinical expression of Alzheimer disease. The Nun Study | Q42435324 | ||
| Glutamate-induced calcium transient triggers delayed calcium overload and neurotoxicity in rat hippocampal neurons | Q42453073 | ||
| Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study | Q43012682 | ||
| Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study | Q43447590 | ||
| Effect of nicardipine treatment on the expression of neurofilament 200 KDa immunoreactivity in the brain of spontaneously hypertensive rats | Q43554810 | ||
| The five-five, ten-ten plan for Alzheimer's disease | Q43562491 | ||
| Micro-architecture and composition of artery walls: relationship to location, diameter and the distribution of mechanical stress | Q43813328 | ||
| The PROGRESS Trial: preventing strokes by lowering blood pressure in patients with cerebral ischemia. Emerging therapies: critique of an important advance. | Q43847102 | ||
| Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: the Atherosclerosis Risk in Communities Study | Q44019951 | ||
| Effect of a calcium channel blocker on the development of ischemic neuron damage in sector CA1 of the horn of Ammon in Mongolian gerbils | Q44117716 | ||
| The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study | Q44175666 | ||
| Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study | Q44357140 | ||
| Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease | Q44438340 | ||
| Calcium-calmodulin binding in ischemic rat neurons after calcium channel blocker therapy | Q44720667 | ||
| Increased beta-secretase activity and expression in rats following transient cerebral ischemia | Q44878523 | ||
| Multicenter clinicopathological correlation in dementia | Q45140975 | ||
| Regional norepinephrine turnover in human hypertension | Q45802257 | ||
| Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. | Q46038693 | ||
| Treatment of vascular risk factors is associated with slower decline in Alzheimer disease | Q46090621 | ||
| Duration of antihypertensive drug use and risk of dementia: A prospective cohort study | Q46626604 | ||
| Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy | Q46689556 | ||
| Acute myocardial infarction and proinflammatory gene variants | Q46868221 | ||
| Mixed brain pathologies account for most dementia cases in community-dwelling older persons | Q48136681 | ||
| Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial | Q48359732 | ||
| beta-Amyloid precursor protein and ss-amyloid peptide immunoreactivity in the rat brain after middle cerebral artery occlusion: effect of age. | Q48384381 | ||
| Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages | Q48388130 | ||
| White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury | Q48575517 | ||
| Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis | Q48586175 | ||
| Neuronal protection correlates with prevention of calcium-calmodulin binding in rats | Q48866430 | ||
| Pericapillary haem-rich deposits: evidence for microhaemorrhages in aging human cerebral cortex | Q48883966 | ||
| Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort | Q48923423 | ||
| Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study | Q48958955 | ||
| Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. | Q50801910 | ||
| Neuroimaging correlates of subjective memory deficits in a community population. | Q51958544 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| calcium channel blocker | Q421700 | ||
| antihypertensive drug | Q575890 | ||
| vascular dementia | Q583908 | ||
| arterial hypertension | Q41861 | ||
| neuroprotective agent | Q50377190 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e107 | |
| P577 | publication date | 2012-04-24 | |
| P1433 | published in | Translational Psychiatry | Q15716636 |
| P1476 | title | Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention | |
| P478 | volume | 2 |
| Q38237225 | Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease. Part I: Pathology, diagnosis and screening |
| Q38237226 | Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease? Part II: Management, prevention and future perspective |
| Q30733242 | Cerebral white matter hyperintensities in the prediction of cognitive decline and incident dementia. |
| Q48124224 | Chronic arterial hypertension impedes glioma growth: a multiparametric MRI study in the rat. |
| Q38731372 | Cognitive Associates of Current and More Intensive Control of Hypertension: Findings From the Hispanic Community Health Study/Study of Latinos |
| Q43622264 | Medication adherence survey of drugs useful in prevention of dementia of Alzheimer's type among Indian patients |
| Q38936146 | Perspectives for treating Alzheimer's disease: a review on promising pharmacological substances |
| Q53499870 | Prevention of Alzheimer's disease, cerebrovascular disease and dementia in women: the case for menopause hormone therapy. |
| Q51754366 | Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. |
| Q30826339 | Therapeutically relevant structural and functional mechanisms triggered by physical and cognitive exercise. |
Search more.